Oncology Research and Treatment
Zhang D. · Kruger S. ·
Schirle K. · Heinemann V. · Dorman K. ·
Westphalen B. ·
Weiss L. · Gebauer L. · Günther M. · Ormanns S. · Werner J. · von Bergwelt-Baildon M. ·
Boeck S. · Haas M.
Log in to MyKarger to check if you already have access to this content.
Buy
FullText & PDF
Unlimited re-access via MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
CHF 38.00 *
EUR 35.00 *
USD 39.00 *
Select
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Learn more
Access via DeepDyve
Unlimited fulltext viewing of this article
Organize, annotate And mark up articles
Printing And downloading restrictions apply
Select
Subscribe
Access to all articles of the subscribed year(s) guaranteed for 5 years
Unlimited re-access via Subscriber Login or MyKarger
Unrestricted printing, no saving restrictions for personal use
read more
Subcription rates
Select
* The final prices may differ from the prices shown due to specifics of VAT rules.
Article / Publication Details
Abstract
Introduction
To this date, surgery remains the only potentially curative approach in the treatment of pancreatic cancer. To analyse the clinical impact of a structured post-operative follow-up program, we retrospectively analysed a cohort of resected pancreatic adenocarcinoma patients treated at LMU Munich.
Methods
Pancreatic adenocarcinoma patients who underwent resection and presented for regular follow-up visits at our center between 2002 and 2017 were identified from two existing study cohorts. Diagnosis of recurrences was categorized by timing (within or outside a scheduled follow up visit) and detection modality (imaging, CA 19-9 increase, or clinical deterioration) and correlated with disease-free survival (DFS) and overall survival (OS).
Results
One-hundred and twenty-five patients with resected pancreatic adenocarcinoma were included in this analysis. Median OS in the whole cohort was 21.1 months. Of these 125 patients, 103 (82.4%) had a documented relapse. Tumour recurrences detected within a scheduled follow up visit (n=86, 83.5%) compared to recurrences becoming apparent at an unplanned visit (n=17, 16.5%) were associated with a significantly improved OS (median 25.5 versus 20.2 months, p=0.019). Compared to patients with recurrence detected by clinical deterioration (n=4, 3.9%), patients with recurrences detected by imaging or laboratory abnormalities (n=99, 96.0%) had a longer median OS (24.8 versus 15.1 months, p=0.007).
Disscusion/Conclusion
A structured follow-up after PDAC resection may have an impact on patient outcome. Prospective trials are needed to evaluate the clinical impact of post-operative follow-up programs.
S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
留言 (0)